Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Cartesian Therapeutics, Inc. (RNAC) had Consolidated Net Income/Loss of $-39.18M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$0.08M |
|
$-39.18M |
|
-- |
|
$0.08M |
|
$26.58M |
|
$-26.50M |
|
$-12.68M |
|
$-39.18M |
|
$-39.18M |
|
$-39.18M |
|
$-39.18M |
|
|
Consolidated Net Income/Loss |
$-39.18M |
$-39.18M |
|
$-26.50M |
|
$-25.88M |
|
26.86M |
|
26.86M |
|
$-1.46 |
|
$-1.46 |
|
| Balance Sheet Financials | |
$122.04M |
|
$11.64M |
|
$166.35M |
|
$288.39M |
|
$15.95M |
|
-- |
|
$420.56M |
|
$436.51M |
|
$-148.12M |
|
$-196.28M |
|
$-148.12M |
|
28.55M |
|
| Cash Flow Statement Financials | |
$-22.14M |
|
$-0.03M |
|
$15.67M |
|
$126.87M |
|
$120.38M |
|
$-6.50M |
|
$2.42M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.65 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-33973.08% |
|
-33973.08% |
|
-- |
|
-50233.33% |
|
-50233.33% |
|
$-22.16M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.30 |
|
301.15 |
|
26.45% |
|
19.96% |
|
-13.59% |
|
26.45% |
|
$-5.19 |
|
$-0.83 |
|
$-0.82 |
|